Mohammad, N. (2021). The Use of Faricimab for the Treatment of Wet age Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). , 21(4), 373-373. doi: 10.52573/ipmj.2021.176975
Najah K. Mohammad. "The Use of Faricimab for the Treatment of Wet age Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)". , 21, 4, 2021, 373-373. doi: 10.52573/ipmj.2021.176975
Mohammad, N. (2021). 'The Use of Faricimab for the Treatment of Wet age Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)', , 21(4), pp. 373-373. doi: 10.52573/ipmj.2021.176975
Mohammad, N. The Use of Faricimab for the Treatment of Wet age Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). , 2021; 21(4): 373-373. doi: 10.52573/ipmj.2021.176975

The Use of Faricimab for the Treatment of Wet age Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

Iraqi Postgraduate Medical Journal
Article 1, Volume 21, Issue 4, 2022, Pages 373-373    PDF (109.84 K)
Document Type: Review Article
DOI: 10.52573/ipmj.2021.176975
Author
Najah K. Mohammad
References
  1. Heier JS, Khanani AM, Ruiz CQ, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TY. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. The Lancet. 2022 ;399:729-40.
  2. Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. The Lancet. 2022 ;399:741-55.
Statistics
Article View: 265
PDF Download: 149


Journal Management System. Powered by iJournalPro.com